ChromaDexÃ‚®'s Novel Ingredient pTeroPureÃ‚® to be Studied as Potential Treatment for Fighting Skin Cancers
IRVINE, Calif., Sept. 8, 2011 /PRNewswire/ -- ChromaDex® Corp. (OTCBB: CDXC) today announced that the University of California, Irvine has granted ChromaDex® the exclusive rights to a joint patent application filed by ChromaDex® and the university for the method of inducing UDP-glucuronosyltransferase (UGT) activity using pTeroPure®, ChromaDex®'s ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits. UGT is an enzyme responsible for the process of glucuronidation, which changes unwanted compounds in to a more water-soluble version, thus allowing for easier elimination from the body. It is known that UGTs prevent melanoma invasiveness by eliminating toxic compounds and are subsequently lost during melanoma progression.
With more than 3.5 million skin cancers diagnosed in more than two million people annually,(1) data shows that there has been at least a 300 percent increase in skin cancer incidence since 1994.(2) Researchers believe that pTeroPure® may show promise for the regression of precancerous diseases such as actinic keratoses (AK) and other changes that are associated with photodamage of the skin. AKs are the earliest identifiable lesions that can eventually develop into skin cancer. These lesions are diagnosed in 14 percent of all visits to dermatologists, following only acne and dermatitis in frequency according to the American Academy of Dermatology.
The pterostilbene-based pTeroPure® may also be used to suppress or prevent progression of these precancerous diseases to non-melanoma skin cancer (NMSC). In prior studies, pterostilbene has been shown to inhibit melanoma cell growth, although the mechanism of action is still being determined.(3)
"As we continue to build on our st